Oligonucleotide-Based Therapy for Diagnosis and Treatment of Cancer
|
Categories |
Oncology, Cancer, Diagnostics |
|
Development Stage |
In vitro proof of concept and small animals |
|
Patent Status |
PCT application filed |
|
Market |
Cancer testing is currently one of the most important growth opportunities diagnostics segment. The worldwide market for in vitro cancer diagnosis is estimated in few billions. |
Highlights
-
Detecting the ratios of specific splicing isoforms used to indicate presence of cancer and sensitivity/resistance to Ras-Raf-MEK and PI3K-mTOR inhibitors.
-
Successfully demonstrated ability to predict activation of specific signaling pathways and the sensitivity of cancer cells to specific drugs.
-
Changing the ratios of specific splicing events by antisense oligonucleotides inhibits cancer cell growth and sensitized them to anti-cancer drugs.
-
Alternative splicing changes are better markers for the activity of drugable signaling pathways.
-
Highly sensitive diagnostic tool
-
New treatment approach
Our Innovation
Novel approach to diagnosing cancer and a patient's sensitivity to specific drugs using the levels in the body of specific splicing isoforms and their ratios as markers; Specific alteration of splicing events by Antisense RNA oligos for the treatment of cancer
Key Features
-
Accurate prediction of tumor sensitivity/resistance to Ras-Raf-MEK and PI3K-mTOR inhibitors.
-
More Accurate diagnosis for efficient treatment to prevent suffering of cancer patients
-
New Efficient treatment for resistant cancer cells.
Development Milestones
Seeking funding for ongoing research, further animal trials, and accumulation of patient data
The Opportunity
Applications in cancer personalized medicine and a new treatment for resistant cancer cells
Patent Status
Granted US 9,745,581
